Fondaparinux
From Wikipedia, the free encyclopedia
| Image:Fondaparinux.png | |
| Fondaparinux
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | 114870-03-0 |
| ATC code | B01AX05 |
| PubChem | 636380 |
| DrugBank | APRD00500 |
| Chemical data | |
| Formula | C31H43N3Na10O49S8 |
| Mol. weight | 1726.77 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 94% |
| Metabolism | ? |
| Half life | 17-21 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Fondaparinux (Arixtra) is a medication that is an anticoagulant.
It is a pentasaccharide composed of five sugars, and the sequence of the five sugars is derived from the portion of heparin that binds to antithrombin. By binding to antithrombin, fondaparinux inhibits factor Xa. (By contrast, low molecular weight heparin has a mean of 15 sugars.)
Fondaparinux is given subcutaneously daily. Clinically, it is used for the prevention of deep vein thrombosis in patients who have had orthopedic surgery as well as for the treatment of deep vein thrombosis and pulmonary embolism.
One potential advantage of fondaparinux over LMWH or unfractionated heparin is that the risk for heparin-induced thrombocytopenia is substantially lower. Furthermore, there have been case reports of fondaparinux being used to anticoagulate patients with established HIT as it has no affinity to PF-4. However, its long half life precludes its use in patients with renal dysfunction. The elimination is done without chemical reactants by renal way.
[edit] Randomized Controlled Trials
Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity.[1]
[edit] External links
